SB-Iban 150 mg (Tablet)
1 tablet kit: ৳ 510.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ibandronic acid |
| Company | Sunman birdem pharma ltd |
Indications
- Treatment of osteoporosis in women (specially postmenopausal)
- Prevention of osteoporosis in women (specially postmenopausal)
- Prevention and treatment of osteoporosis in men
Pharmacology
- Inhibition of bone resorption
- Prevention of bone destruction
- Inhibition of osteoclast activity
- High potency and therapeutic margin
- Selective action on bone tissue
- Reduction of bone resorption with no direct effect on bone formation
Dosage & Administration
- Recommended dose of one 150 mg film-coated tablet once a month
- Tablet should be taken with a full glass of plain water
- Tablet should be taken 60 minutes before the first food or drink of the day or any oral medication
Interaction
- Likely interference with calcium supplements and some oral medications
- No interaction potential with tamoxifen or hormone replacement therapy
- Increase in bioavailability with ranitidine
- No likely drug interactions of clinical significance
Contraindications
- Known hypersensitivity to ibandronic acid or excipients
- Uncorrected hypocalcemia
- Abnormalities of the esophagus delaying esophageal emptying
- Inability to stand or sit upright for at least 60 minutes
Side Effects
- Dyspepsia
- Nausea
- Diarrhea
- Abdominal pain
- Muscle aches
- Headaches
- Dizziness
Pregnancy & Lactation
- Not to be used during pregnancy
- No clinical experience in pregnant women
- Not to be used during lactation
- Highest concentration in breast milk seen in first 2 hours after administration
Precautions & Warnings
- Treatment of hypocalcemia and bone/mineral disturbances before therapy
- Caution in patients with active upper gastrointestinal problems
- Alertness to signs of possible esophageal reaction
- Caution with concomitant use of NSAIDs
- Risk of osteonecrosis of the jaw
- No established safety and efficacy in patients less than 18 years old
Use in Special Populations
- No dosage adjustment for patients with mild or moderate renal impairment
- No dosage adjustment for patients with hepatic impairment
- No dosage adjustment for elderly patients
- Safety and efficacy not established in patients less than 18 years old
Overdose Effects
- Oral overdosage may result in upper gastrointestinal adverse events
- Milk or antacids can be given to bind the medicine
- Vomiting should not be induced
Therapeutic Class
- Bisphosphonate preparations
Storage Conditions
- Keep below 30°C temperature
- Away from light & moisture
- Keep out of the reach of children